{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:42:18Z","timestamp":1794487338472,"version":"4.9.1"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T00:00:00Z","timestamp":1581897600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T00:00:00Z","timestamp":1581897600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1038\/s41584-020-0373-9","type":"journal-article","created":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T09:07:15Z","timestamp":1581930435000},"page":"145-154","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":665,"title":["Methotrexate and its mechanisms of action in inflammatory arthritis"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4295-7383","authenticated-orcid":false,"given":"Bruce N.","family":"Cronstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4968-4306","authenticated-orcid":false,"given":"Thomas M.","family":"Aune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,17]]},"reference":[{"key":"373_CR1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13075-018-1599-7","volume":"20","author":"ME Weinblatt","year":"2018","unstructured":"Weinblatt, M. E. Methotrexate: who would have predicted its importance in rheumatoid arthritis? Arthritis Res. Ther. 20, 103 (2018).","journal-title":"Arthritis Res. Ther."},{"key":"373_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/acr.22783","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh, J. A. et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 68, 1\u201325 (2016).","journal-title":"Arthritis Care Res."},{"key":"373_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.semarthrit.2013.01.002","volume":"43","author":"KJ Aaltonen","year":"2013","unstructured":"Aaltonen, K. J. et al. Do biologic drugs affect the need for and outcome of joint replacements in patients with rheumatoid arthritis? A register-based study. Semin. Arthritis Rheum. 43, 55\u201362 (2013).","journal-title":"Semin. Arthritis Rheum."},{"key":"373_CR4","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1002\/acr.22596","volume":"67","author":"S Asai","year":"2015","unstructured":"Asai, S. et al. Effects of concomitant methotrexate on large joint replacement in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a multicenter retrospective cohort study in Japan. Arthritis Care Res. 67, 1363\u20131370 (2015).","journal-title":"Arthritis Care Res."},{"key":"373_CR5","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.3899\/jrheum.150410","volume":"42","author":"S Asai","year":"2015","unstructured":"Asai, S. et al. Concomitant methotrexate protects against total knee arthroplasty in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors. J. Rheumatol. 42, 2255\u20132260 (2015).","journal-title":"J. Rheumatol."},{"key":"373_CR6","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/jps.2600780219","volume":"78","author":"RA Herman","year":"1989","unstructured":"Herman, R. A., Veng-Pedersen, P., Hoffman, J., Koehnke, R. & Furst, D. E. Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. J. Pharm. Sci. 78, 165\u2013171 (1989).","journal-title":"J. Pharm. Sci."},{"key":"373_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00296-016-3621-1","volume":"37","author":"MH Schiff","year":"2017","unstructured":"Schiff, M. H. & Sadowski, P. Oral to subcutaneous methotrexate dose-conversion strategy in the treatment of rheumatoid arthritis. Rheumatol. Int. 37, 213\u2013218 (2017).","journal-title":"Rheumatol. Int."},{"key":"373_CR8","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1002\/art.1780290703","volume":"29","author":"JM Kremer","year":"1986","unstructured":"Kremer, J. M., Galivan, J., Streckfuss, A. & Kamen, B. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum. 29, 832\u2013835 (1986).","journal-title":"Arthritis Rheum."},{"key":"373_CR9","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1172\/JCI112088","volume":"76","author":"BA Chabner","year":"1985","unstructured":"Chabner, B. A. et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? J. Clin. Invest. 76, 907\u2013912 (1985).","journal-title":"J. Clin. Invest."},{"key":"373_CR10","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/0014-4827(69)90039-1","volume":"56","author":"JA Steffen","year":"1969","unstructured":"Steffen, J. A. & Stolzmann, W. M. Studies on in vitro lymphocyte proliferation in cultures synchronized by the inhibition of DNA synthesis. I. Variability of S plus G2 periods of first generation cells. Exp. Cell Res. 56, 453\u2013460 (1969).","journal-title":"Exp. Cell Res."},{"key":"373_CR11","first-page":"441","volume":"25","author":"SL Morgan","year":"1998","unstructured":"Morgan, S. L., Baggott, J. E., Lee, J. Y. & Alarcon, G. S. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J. Rheumatol. 25, 441\u2013446 (1998).","journal-title":"J. Rheumatol."},{"key":"373_CR12","doi-asserted-by":"publisher","first-page":"833","DOI":"10.7326\/0003-4819-121-11-199412010-00002","volume":"121","author":"SL Morgan","year":"1994","unstructured":"Morgan, S. L. et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann. Int. Med. 121, 833\u2013841 (1994).","journal-title":"Ann. Int. Med."},{"key":"373_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/art.1780330102","volume":"33","author":"SL Morgan","year":"1990","unstructured":"Morgan, S. L. et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 33, 9\u201318 (1990).","journal-title":"Arthritis Rheum."},{"key":"373_CR14","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/art.1780360609","volume":"36","author":"JB Shiroky","year":"1993","unstructured":"Shiroky, J. B. et al. Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 36, 795\u2013803 (1993).","journal-title":"Arthritis Rheum."},{"key":"373_CR15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/jebm.12060","volume":"6","author":"B Shea","year":"2013","unstructured":"Shea, B. Folic acid or folinic acid for reducing side effects of methotrexate for people with rheumatoid arthritis. J. Evid. Based Med. 6, 202\u2013203 (2013).","journal-title":"J. Evid. Based Med."},{"key":"373_CR16","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1136\/ard.50.12.913","volume":"50","author":"DA Joyce","year":"1991","unstructured":"Joyce, D. A., Will, R. K., Hoffman, D. M., Laing, B. & Blackbourn, S. J. Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. Ann. Rheum. Dis. 50, 913\u2013914 (1991).","journal-title":"Ann. Rheum. Dis."},{"key":"373_CR17","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/art.1780310712","volume":"31","author":"M Tishler","year":"1988","unstructured":"Tishler, M., Caspi, D., Fishel, B. & Yaron, M. The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients. Arthritis Rheum. 31, 906\u2013908 (1988).","journal-title":"Arthritis Rheum."},{"key":"373_CR18","first-page":"689","volume":"19","author":"K Yukioka","year":"1992","unstructured":"Yukioka, K. et al. Polyamine levels in synovial tissues and synovial fluids of patients with rheumatoid arthritis. J. Rheumatol. 19, 689\u2013692 (1992).","journal-title":"J. Rheumatol."},{"key":"373_CR19","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/art.1780330706","volume":"33","author":"G Nesher","year":"1990","unstructured":"Nesher, G. & Moore, T. L. The in vitro effects of methotrexate on peripheral blood mononuclear cells. Modulation by methyl donors and spermidine. Arthritis Rheum. 33, 954\u2013959 (1990).","journal-title":"Arthritis Rheum."},{"key":"373_CR20","first-page":"1661","volume":"20","author":"Y Furumitsu","year":"1993","unstructured":"Furumitsu, Y. et al. Levels of urinary polyamines in patients with rheumatoid arthritis. J. Rheumatol. 20, 1661\u20131665 (1993).","journal-title":"J. Rheumatol."},{"key":"373_CR21","first-page":"395","volume":"14","author":"G Nesher","year":"1996","unstructured":"Nesher, G., Osborn, T. G. & Moore, T. L. In vitro effects of methotrexate on polyamine levels in lymphocytes from rheumatoid arthritis patients. Clin. Exp. Rheumatol. 14, 395\u2013399 (1996).","journal-title":"Clin. Exp. Rheumatol."},{"key":"373_CR22","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1136\/ard.50.9.637","volume":"50","author":"G Nesher","year":"1991","unstructured":"Nesher, G., Moore, T. L. & Dorner, R. W. In vitro effects of methotrexate on peripheral blood monocytes: modulation by folinic acid and S-adenosylmethionine. Ann. Rheum. Dis. 50, 637\u2013641 (1991).","journal-title":"Ann. Rheum. Dis."},{"key":"373_CR23","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nrrheum.2010.5","volume":"6","author":"ES Chan","year":"2010","unstructured":"Chan, E. S. & Cronstein, B. N. Methotrexate\u2013how does it really work? Nat. Rev. Rheumatol. 6, 175\u2013178 (2010).","journal-title":"Nat. Rev. Rheumatol."},{"key":"373_CR24","doi-asserted-by":"publisher","first-page":"4881","DOI":"10.1073\/pnas.82.15.4881","volume":"82","author":"CJ Allegra","year":"1985","unstructured":"Allegra, C. J., Drake, J. C., Jolivet, J. & Chabner, B. A. Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc. Natl Acad. Sci. USA 82, 4881\u20134885 (1985).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"373_CR25","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1172\/JCI116884","volume":"92","author":"BN Cronstein","year":"1993","unstructured":"Cronstein, B. N., Naime, D. & Ostad, E. The antiinflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J. Clin. Invest. 92, 2675\u20132682 (1993).","journal-title":"J. Clin. Invest."},{"key":"373_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrrheum.2016.178","volume":"13","author":"BN Cronstein","year":"2017","unstructured":"Cronstein, B. N. & Sitkovsky, M. Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases. Nat. Rev. Rheumatol. 13, 41\u201351 (2017).","journal-title":"Nat. Rev. Rheumatol."},{"key":"373_CR27","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1002\/1529-0131(200003)43:3<656::AID-ANR23>3.0.CO;2-H","volume":"43","author":"MC Montesinos","year":"2000","unstructured":"Montesinos, M. C. et al. Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. Arthritis Rheum. 43, 656\u2013663 (2000).","journal-title":"Arthritis Rheum."},{"key":"373_CR28","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1002\/art.22643","volume":"56","author":"MC Montesinos","year":"2007","unstructured":"Montesinos, M. C. et al. The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5\u2019-nucleotidase: findings in a study of ecto-5\u2019-nucleotidase gene-deficient mice. Arthritis Rheum. 56, 1440\u20131445 (2007).","journal-title":"Arthritis Rheum."},{"key":"373_CR29","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1186\/ar1914","volume":"8","author":"MC Montesinos","year":"2006","unstructured":"Montesinos, M. C., Desai, A. & Cronstein, B. N. Suppression of inflammation by low-dose methotrexate is mediated by adenosine A2A receptor but not A3 receptor activation in thioglycollate-induced peritonitis. Arthritis Res. Ther. 8, R53 (2006).","journal-title":"Arthritis Res. Ther."},{"key":"373_CR30","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/art.10712","volume":"48","author":"MC Montesinos","year":"2003","unstructured":"Montesinos, M. C. et al. Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum. 48, 240\u2013247 (2003).","journal-title":"Arthritis Rheum."},{"key":"373_CR31","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1136\/ard.2005.048637","volume":"65","author":"NP Riksen","year":"2006","unstructured":"Riksen, N. P. et al. Methotrexate modulates the kinetics of adenosine in humans in vivo. Ann. Rheum. Dis. 65, 465\u2013470 (2006).","journal-title":"Ann. Rheum. Dis."},{"key":"373_CR32","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/art.10766","volume":"48","author":"G Nesher","year":"2003","unstructured":"Nesher, G., Mates, M. & Zevin, S. Effect of caffeine consumption on efficacy of methotrexate in rheumatoid arthritis. Arthritis Rheum. 48, 571\u2013572 (2003).","journal-title":"Arthritis Rheum."},{"key":"373_CR33","first-page":"1275","volume":"33","author":"E Benito-Garcia","year":"2006","unstructured":"Benito-Garcia, E. et al. Dietary caffeine intake does not affect methotrexate efficacy in patients with rheumatoid arthritis. J. Rheumatol. 33, 1275\u20131281 (2006).","journal-title":"J. Rheumatol."},{"key":"373_CR34","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/icb.2017.8","volume":"95","author":"D Allard","year":"2017","unstructured":"Allard, D., Turcotte, M. & Stagg, J. Targeting A2 adenosine receptors in cancer. Immunol. Cell Biol. 95, 333\u2013339 (2017).","journal-title":"Immunol. Cell Biol."},{"key":"373_CR35","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1073\/pnas.1424792112","volume":"112","author":"RS Peres","year":"2015","unstructured":"Peres, R. S. et al. Low expression of CD39 on regulatory T cells as a biomarker for resistance to methotrexate therapy in rheumatoid arthritis. Proc. Natl Acad. Sci. USA 112, 2509\u20132514 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"373_CR36","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1136\/annrheumdis-2018-213183","volume":"77","author":"S Bitoun","year":"2018","unstructured":"Bitoun, S. et al. Methotrexate and BAFF interaction prevents immunization against TNF inhibitors. Ann. Rheum. Dis. 77, 1463\u20131470 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"373_CR37","doi-asserted-by":"publisher","first-page":"9056","DOI":"10.1073\/pnas.0409594102","volume":"102","author":"K Chalupsky","year":"2005","unstructured":"Chalupsky, K. & Cai, H. Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. Proc. Natl Acad. Sci. USA 102, 9056\u20139061 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"373_CR38","doi-asserted-by":"publisher","first-page":"28128","DOI":"10.1074\/jbc.M109.041483","volume":"284","author":"MJ Crabtree","year":"2009","unstructured":"Crabtree, M. J., Tatham, A. L., Hale, A. B., Alp, N. J. & Channon, K. M. Critical role for tetrahydrobiopterin recycling by dihydrofolate reductase in regulation of endothelial nitric-oxide synthase coupling \u2013 relative importance of the de novo biopterin synthesis versus salvage pathways. J. Biol. Chem. 284, 28128\u201328136 (2009).","journal-title":"J. Biol. Chem."},{"key":"373_CR39","doi-asserted-by":"publisher","first-page":"12691","DOI":"10.1074\/jbc.M809295200","volume":"284","author":"T Sugiyama","year":"2009","unstructured":"Sugiyama, T., Levy, B. D. & Michel, T. Tetrahydrobiopterin recycling, a key determinant of endothelial nitric-oxide synthase-dependent signaling pathways in cultured vascular endothelial cells. J. Biol. Chem. 284, 12691\u201312700 (2009).","journal-title":"J. Biol. Chem."},{"key":"373_CR40","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1002\/art.30457","volume":"63","author":"CF Spurlock","year":"2011","unstructured":"Spurlock, C. F. et al. Increased sensitivity to apoptosis induced by methotrexate is mediated by JNK. Arthritis Rheum. 63, 2606\u20132616 (2011).","journal-title":"Arthritis Rheum."},{"key":"373_CR41","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1002\/art.34342","volume":"64","author":"CF Spurlock","year":"2012","unstructured":"Spurlock, C. F., Tossberg, J. T., Fuchs, H. A., Olsen, N. J. & Aune, T. M. Methotrexate increases expression of cell cycle checkpoint genes via JNK activation. Arthritis Rheum. 64, 1780\u20131789 (2012).","journal-title":"Arthritis Rheum."},{"key":"373_CR42","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/rheumatology\/keu279","volume":"54","author":"CF Spurlock","year":"2015","unstructured":"Spurlock, C. F. et al. Methotrexate-mediated inhibition of nuclear factor \u03baB activation by distinct pathways in T cells and fibroblast-like synoviocytes. Rheumatology 54, 178\u2013187 (2015).","journal-title":"Rheumatology"},{"key":"373_CR43","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev-biochem-051410-092902","volume":"81","author":"JL Rinn","year":"2012","unstructured":"Rinn, J. L. & Chang, H. Y. Genome regulation by long noncoding RNAs. Annu. Rev. Biochem. 81, 145\u2013166 (2012).","journal-title":"Annu. Rev. Biochem."},{"key":"373_CR44","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.cell.2010.06.040","volume":"142","author":"M Huarte","year":"2010","unstructured":"Huarte, M. et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell 142, 409\u2013419 (2010).","journal-title":"Cell"},{"key":"373_CR45","first-page":"16","volume":"124","author":"ME Weinblatt","year":"2013","unstructured":"Weinblatt, M. E. Methotrexate in rheumatoid arthritis: a quarter century of development. Trans. Am. Clin. Climatol. Assoc. 124, 16\u201325 (2013).","journal-title":"Trans. Am. Clin. Climatol. Assoc."},{"key":"373_CR46","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.molcel.2013.11.004","volume":"53","author":"F Yang","year":"2014","unstructured":"Yang, F., Zhang, H. F., Mei, Y. D. & Wu, M. Reciprocal regulation of HIF-1\u03b1 and lincRNA-p21 modulates the Warburg effect. Mol. Cell 53, 88\u2013100 (2014).","journal-title":"Mol. Cell"},{"key":"373_CR47","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.molcel.2012.06.027","volume":"47","author":"JH Yoon","year":"2012","unstructured":"Yoon, J. H. et al. LincRNA-p21 suppresses target mRNA translation. Mol. Cell 47, 648\u2013655 (2012).","journal-title":"Mol. Cell"},{"key":"373_CR48","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1002\/art.38805","volume":"66","author":"CF Spurlock","year":"2014","unstructured":"Spurlock, C. F., Tossberg, J. T., Matlock, B. K., Olsen, N. J. & Aune, T. M. Methotrexate inhibits NF-\u03baB activity via long intergenic (noncoding) RNA-p21 induction. Arthritis Rheumatol. 66, 2947\u20132957 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"373_CR49","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/1759720X18776224","volume":"10","author":"CJ Malemud","year":"2018","unstructured":"Malemud, C. J. The role of the JAK\/STAT signal pathway in rheumatoid arthritis. Ther. Adv. Musculoskelet. Dis. 10, 117\u2013127 (2018).","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"373_CR50","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/JLB.5RU0519-145R","volume":"106","author":"E Gremese","year":"2019","unstructured":"Gremese, E., Alivernini, S., Tolusso, B., Zeidler, M. P. & Ferraccioli, G. JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy. J. Leukoc. Biol. 106, 1063\u20131068 (2019).","journal-title":"J. Leukoc. Biol."},{"key":"373_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0130078","volume":"10","author":"S Thomas","year":"2015","unstructured":"Thomas, S. et al. Methotrexate Is a JAK\/STAT pathway inhibitor. PLoS One 10, e0130078 (2015).","journal-title":"PLoS One"},{"key":"373_CR52","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1002\/jcp.24568","volume":"229","author":"SM Hassanian","year":"2014","unstructured":"Hassanian, S. M., Dinarvand, P. & Rezaie, A. R. Adenosine regulates the proinflammatory signaling function of thrombin in endothelial cells. J. Cell Physiol. 229, 1292\u20131300 (2014).","journal-title":"J. Cell Physiol."},{"key":"373_CR53","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/apha.12176","volume":"210","author":"J Yang","year":"2014","unstructured":"Yang, J. et al. Adenosine increases LPS-induced nuclear factor kappa B activation in smooth muscle cells via an intracellular mechanism and modulates it via actions on adenosine receptors. Acta Physiol. 210, 590\u2013599 (2014).","journal-title":"Acta Physiol."},{"key":"373_CR54","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1111\/bph.12227","volume":"169","author":"A Mediero","year":"2013","unstructured":"Mediero, A., Perez-Aso, M. & Cronstein, B. N. Activation of adenosine A2A receptor reduces osteoclast formation via PKA- and ERK1\/2-mediated suppression of NF\u03baB nuclear translocation. Br. J. Pharmacol. 169, 1372\u20131388 (2013).","journal-title":"Br. J. Pharmacol."},{"key":"373_CR55","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.transproceed.2010.02.084","volume":"42","author":"LM Tang","year":"2010","unstructured":"Tang, L. M. et al. Activation of adenosine A2A receptor attenuates inflammatory response in a rat model of small-for-size liver transplantation. Transpl. Proc. 42, 1915\u20131920 (2010).","journal-title":"Transpl. Proc."},{"key":"373_CR56","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1097\/SHK.0b013e3181b8f2fb","volume":"33","author":"R Di Paola","year":"2010","unstructured":"Di Paola, R. et al. Adenosine A2A receptor-selective stimulation reduces signaling pathways involved in the development of intestine ischemia and reperfusion injury. Shock 33, 541\u2013551 (2010).","journal-title":"Shock"},{"key":"373_CR57","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1091\/mbc.e06-07-0596","volume":"18","author":"M Ramanathan","year":"2007","unstructured":"Ramanathan, M., Pinhal-Enfield, G., Hao, I. & Leibovich, S. J. Synergistic up-regulation of vascular endothelial growth factor (VEGF) expression in macrophages by adenosine A2A receptor agonists and endotoxin involves transcriptional regulation via the hypoxia response element in the VEGF promoter. Mol. Biol. Cell 18, 14\u201323 (2007).","journal-title":"Mol. Biol. Cell"},{"key":"373_CR58","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1161\/CIRCULATIONAHA.105.595249","volume":"113","author":"A Zernecke","year":"2006","unstructured":"Zernecke, A. et al. CD73\/ecto-5\u2019-nucleotidase protects against vascular inflammation and neointima formation. Circulation 113, 2120\u20132127 (2006).","journal-title":"Circulation"},{"key":"373_CR59","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1124\/mol.104.001107","volume":"66","author":"WA Sands","year":"2004","unstructured":"Sands, W. A., Martin, A. F., Strong, E. W. & Palmer, T. M. Specific inhibition of nuclear factor-\u03baB-dependent inflammatory responses by cell type-specific mechanisms upon A2A adenosine receptor gene transfer. Mol. Pharmacol. 66, 1147\u20131159 (2004).","journal-title":"Mol. Pharmacol."},{"key":"373_CR60","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4049\/jimmunol.173.1.21","volume":"173","author":"D Lukashev","year":"2004","unstructured":"Lukashev, D., Ohta, A., Apasov, S., Chen, J. F. & Sitkovsky, M. Cutting edge: physiologic attenuation of proinflammatory transcription by the Gs protein-coupled A2A adenosine receptor in vivo. J. Immunol. 173, 21\u201324 (2004).","journal-title":"J. Immunol."},{"key":"373_CR61","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1189\/jlb.72.5.1027","volume":"72","author":"K Bshesh","year":"2002","unstructured":"Bshesh, K. et al. The A2A receptor mediates an endogenous regulatory pathway of cytokine expression in THP-1 cells. J. Leukoc. Biol. 72, 1027\u20131036 (2002).","journal-title":"J. Leukoc. Biol."},{"key":"373_CR62","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/tpj.2010.80","volume":"12","author":"D Plant","year":"2012","unstructured":"Plant, D. et al. A genetic marker at the OLIG3\/TNFAIP3 locus associates with methotrexate continuation in early inflammatory polyarthritis: results from the Norfolk arthritis register. Pharmacogenomics J. 12, 128\u2013133 (2012).","journal-title":"Pharmacogenomics J."},{"key":"373_CR63","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1136\/annrheumdis-2015-208736","volume":"75","author":"C Municio","year":"2016","unstructured":"Municio, C. et al. Methotrexate selectively targets human proinflammatory macrophages through a thymidylate synthase\/p53 axis. Ann. Rheum. Dis. 75, 2157\u20132165 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"373_CR64","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1136\/annrheumdis-2017-212537","volume":"77","author":"C Municio","year":"2018","unstructured":"Municio, C. et al. Methotrexate limits inflammation through an A20-dependent cross-tolerance mechanism. Ann. Rheum. Dis. 77, 752\u2013759 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"373_CR65","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/rheumatology\/keu279","volume":"54","author":"CF Spurlock III","year":"2015","unstructured":"Spurlock, C. F. III et al. Methotrexate-mediated inhibition of nuclear factor \u03baB activation by distinct pathways in T cells and fibroblast-like synoviocytes. Rheumatology 54, 178\u2013187 (2015).","journal-title":"Rheumatology"},{"key":"373_CR66","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.cell.2009.04.037","volume":"137","author":"KH Vousden","year":"2009","unstructured":"Vousden, K. H. & Prives, C. Blinded by the light: the growing complexity of p53. Cell 137, 413\u2013431 (2009).","journal-title":"Cell"},{"key":"373_CR67","doi-asserted-by":"publisher","first-page":"aaa5612","DOI":"10.1126\/science.aaa5612","volume":"349","author":"C Kang","year":"2015","unstructured":"Kang, C. et al. The DNA damage response induces inflammation and senescence by inhibiting autophagy of GATA4. Science 349, aaa5612 (2015).","journal-title":"Science"},{"key":"373_CR68","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.ccr.2013.03.022","volume":"23","author":"T Cooks","year":"2013","unstructured":"Cooks, T. et al. Mutant p53 prolongs NF-\u03baB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 23, 634\u2013646 (2013).","journal-title":"Cancer Cell"},{"key":"373_CR69","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/CCO.0b013e32835b6386","volume":"25","author":"D Menendez","year":"2013","unstructured":"Menendez, D., Shatz, M. & Resnick, M. A. Interactions between the tumor suppressor p53 and immune responses. Curr. Opin. Oncol. 25, 85\u201392 (2013).","journal-title":"Curr. Opin. Oncol."},{"key":"373_CR70","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1093\/carcin\/bgu134","volume":"35","author":"T Cooks","year":"2014","unstructured":"Cooks, T., Harris, C. C. & Oren, M. Caught in the cross fire: p53 in inflammation. Carcinogenesis 35, 1680\u20131690 (2014).","journal-title":"Carcinogenesis"},{"key":"373_CR71","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1615\/CritRevImmunol.2014012193","volume":"34","author":"H Takatori","year":"2014","unstructured":"Takatori, H., Kawashima, H., Suzuki, K. & Nakajima, H. Role of p53 in systemic autoimmune diseases. Crit. Rev. Immunol. 34, 509\u2013516 (2014).","journal-title":"Crit. Rev. Immunol."},{"key":"373_CR72","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1172\/JCI83404","volume":"126","author":"G Rackov","year":"2016","unstructured":"Rackov, G. et al. p21 mediates macrophage reprogramming through regulation of p50-p50 NF-\u03baB and IFN-\u03b2. J. Clin. Invest. 126, 3089\u20133103 (2016).","journal-title":"J. Clin. Invest."},{"key":"373_CR73","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1126\/science.1121513","volume":"311","author":"ZH Wu","year":"2006","unstructured":"Wu, Z. H., Shi, Y. L., Tibbetts, R. S. & Miyamoto, S. Molecular linkage between the kinase ATM and NF-\u03baB signaling in response to genotoxic stimuli. Science 311, 1141\u20131146 (2006).","journal-title":"Science"},{"key":"373_CR74","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s13075-016-1161-4","volume":"18","author":"T Zhang","year":"2016","unstructured":"Zhang, T. et al. p53 predominantly regulates IL-6 production and suppresses synovial inflammation in fibroblast-like synoviocytes and adjuvant-induced arthritis. Arthritis Res. Ther. 18, 271 (2016).","journal-title":"Arthritis Res. Ther."},{"key":"373_CR75","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/nri2094","volume":"7","author":"IB McInnes","year":"2007","unstructured":"McInnes, I. B. & Schett, G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7, 429\u2013442 (2007).","journal-title":"Nat. Rev. Immunol."},{"key":"373_CR76","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.2337\/diabetes.54.5.1423","volume":"54","author":"SJ Zheng","year":"2005","unstructured":"Zheng, S. J., Lamhamedi-Cherradi, S. E., Wang, P., Xu, L. Y. & Chen, Y. H. Tumor suppressor p53 inhibits autoimmune inflammation and macrophage function. Diabetes 54, 1423\u20131428 (2005).","journal-title":"Diabetes"},{"key":"373_CR77","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0165-5728(02)00428-9","volume":"135","author":"Y Okuda","year":"2003","unstructured":"Okuda, Y., Okuda, M. & Bernard, C. C. A. Regulatory role of p53 in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 135, 29\u201337 (2003).","journal-title":"J. Neuroimmunol."},{"key":"373_CR78","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.4049\/jimmunol.1300509","volume":"191","author":"H Kawashima","year":"2013","unstructured":"Kawashima, H. et al. Tumor suppressor p53 inhibits systemic autoimmune diseases by inducing regulatory T cells. J. Immunol. 191, 3614\u20133623 (2013).","journal-title":"J. Immunol."},{"key":"373_CR79","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/nri.2016.99","volume":"16","author":"C Munoz-Fontela","year":"2016","unstructured":"Munoz-Fontela, C., Mandinova, A., Aaronson, S. A. & Lee, S. W. Emerging roles of p53 and other tumour-suppressor genes in immune regulation. Nat. Rev. Immunol. 16, 741\u2013750 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"373_CR80","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.0105-2896.2009.00859.x","volume":"233","author":"B Bartok","year":"2010","unstructured":"Bartok, B. & Firestein, G. S. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol. Rev. 233, 233\u2013255 (2010).","journal-title":"Immunol. Rev."},{"key":"373_CR81","doi-asserted-by":"publisher","first-page":"R17","DOI":"10.1186\/ar4444","volume":"16","author":"NJ Olsen","year":"2014","unstructured":"Olsen, N. J., Spurlock, C. F. & Aune, T. M. Methotrexate induces production of IL-1 and IL-6 in the monocytic cell line U937. Arthritis Res. Ther. 16, R17 (2014).","journal-title":"Arthritis Res. Ther."},{"key":"373_CR82","first-page":"1308","volume":"40","author":"JT Merrill","year":"1997","unstructured":"Merrill, J. T. et al. Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes: a mechanism for methotrexate-induced nodulosis in rheumatoid arthritis. Arthritis Rheum. 40, 1308\u20131315 (1997).","journal-title":"Arthritis Rheum."},{"key":"373_CR83","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0006-8993(93)91651-8","volume":"612","author":"V Chagoya de Sanchez","year":"1993","unstructured":"Chagoya de Sanchez, V. et al. Day-night variations of adenosine and its metabolizing enzymes in the brain cortex of the rat\u2013possible physiological significance for the energetic homeostasis and the sleep-wake cycle. Brain Res. 612, 115\u2013121 (1993).","journal-title":"Brain Res."},{"key":"373_CR84","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1139\/y95-044","volume":"73","author":"V Chagoya de Sanchez","year":"1995","unstructured":"Chagoya de Sanchez, V. Circadian variations of adenosine and of its metabolism. Could adenosine be a molecular oscillator for circadian rhythms? Can. J. Physiol. Pharmacol. 73, 339\u2013355 (1995).","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"373_CR85","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3109\/07420529609012650","volume":"13","author":"V Chagoya de Sanchez","year":"1996","unstructured":"Chagoya de Sanchez, V. et al. Temporal variations of adenosine metabolism in human blood. Chronobiol. Int. 13, 163\u2013177 (1996).","journal-title":"Chronobiol. Int."},{"key":"373_CR86","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/sj.bjp.0706812","volume":"148","author":"ES Chan","year":"2006","unstructured":"Chan, E. S. et al. Adenosine A2A receptors play a role in the pathogenesis of hepatic cirrhosis. Br. J. Pharmacol. 148, 1144\u20131155 (2006).","journal-title":"Br. J. Pharmacol."},{"key":"373_CR87","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1124\/mol.107.038760","volume":"72","author":"J Che","year":"2007","unstructured":"Che, J., Chan, E. S. & Cronstein, B. N. Adenosine A2A receptor occupancy stimulates collagen expression by hepatic stellate cells via pathways involving protein kinase A, Src, and extracellular signal-regulated kinases 1\/2 signaling cascade or p38 mitogen-activated protein kinase signaling pathway. Mol. Pharmacol. 72, 1626\u20131636 (2007).","journal-title":"Mol. Pharmacol."},{"key":"373_CR88","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1136\/ard.52.4.315-b","volume":"52","author":"SL Morgan","year":"1993","unstructured":"Morgan, S. L., Baggott, J. E., Koopman, W. J., Krumdieck, C. L. & Alarcon, G. S. Folate supplementation and methotrexate. Ann. Rheum. Dis. 52, 315\u2013316 (1993).","journal-title":"Ann. Rheum. Dis."},{"key":"373_CR89","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/art.1780400229","volume":"40","author":"GS Alarcon","year":"1997","unstructured":"Alarcon, G. S. & Morgan, S. L. Guidelines for folate supplementation in rheumatoid arthritis patients treated with methotrexate: comment on the guidelines for monitoring drug therapy. Arthritis Rheum. 40, 391 (1997).","journal-title":"Arthritis Rheum."},{"key":"373_CR90","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11926-017-0646-8","volume":"19","author":"J Roszkiewicz","year":"2017","unstructured":"Roszkiewicz, J. & Smolewska, E. In the pursuit of methotrexate treatment response biomarker in Juvenile idiopathic arthritis \u2014 are we getting closer to personalised medicine? Curr. Rheumatol. Rep. 19, 19 (2017).","journal-title":"Curr. Rheumatol. Rep."},{"key":"373_CR91","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/s41397-018-0025-5","volume":"18","author":"JC Taylor","year":"2018","unstructured":"Taylor, J. C. et al. Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients. Pharmacogenomics J. 18, 528\u2013538 (2018).","journal-title":"Pharmacogenomics J."},{"key":"373_CR92","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/art.40810","volume":"71","author":"D Plant","year":"2019","unstructured":"Plant, D. et al. Profiling of gene expression biomarkers as a classifier of methotrexate nonresponse in patients with rheumatoid arthritis. Arthritis Rheumatol. 71, 678\u2013684 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"373_CR93","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208534","volume":"13","author":"M de Rotte","year":"2018","unstructured":"de Rotte, M. et al. Development and validation of a prognostic multivariable model to predict insufficient clinical response to methotrexate in rheumatoid arthritis. PLoS One 13, e0208534 (2018).","journal-title":"PLoS One"},{"key":"373_CR94","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13075-018-1645-5","volume":"20","author":"JC Sergeant","year":"2018","unstructured":"Sergeant, J. C. et al. Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS). Arthritis Res. Ther. 20, 147 (2018).","journal-title":"Arthritis Res. Ther."},{"key":"373_CR95","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1136\/annrheumdis-2018-213035","volume":"77","author":"XM Teitsma","year":"2018","unstructured":"Teitsma, X. M. et al. Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors. Ann. Rheum. Dis. 77, 1261\u20131267 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"373_CR96","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.autrev.2009.04.006","volume":"9","author":"P Szodoray","year":"2010","unstructured":"Szodoray, P. et al. Anti-citrullinated protein\/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis. Autoimmun. Rev. 9, 140\u2013143 (2010).","journal-title":"Autoimmun. Rev."},{"key":"373_CR97","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/j.1756-185X.2010.01553.x","volume":"13","author":"S Luban","year":"2010","unstructured":"Luban, S. & Li, Z. G. Citrullinated peptide and its relevance to rheumatoid arthritis: an update. Int. J. Rheum. Dis. 13, 284\u2013287 (2010).","journal-title":"Int. J. Rheum. Dis."},{"key":"373_CR98","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/S0952-7915(00)00191-6","volume":"13","author":"S Gallucci","year":"2001","unstructured":"Gallucci, S. & Matzinger, P. Danger signals: SOS to the immune system. Curr. Opin. Immunol. 13, 114\u2013119 (2001).","journal-title":"Curr. Opin. Immunol."},{"key":"373_CR99","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/ni0107-11","volume":"8","author":"P Matzinger","year":"2007","unstructured":"Matzinger, P. Friendly and dangerous signals: is the tissue in control? Nat. Immunol. 8, 11\u201313 (2007).","journal-title":"Nat. Immunol."},{"key":"373_CR100","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/00000441-195102000-00009","volume":"221","author":"R Gubner","year":"1951","unstructured":"Gubner, R., August, S. & Ginsberg, V. Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am. J. Med. Sci. 221, 176\u2013182 (1951).","journal-title":"Am. J. Med. Sci."},{"key":"373_CR101","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1056\/NEJM198503283121303","volume":"312","author":"ME Weinblatt","year":"1985","unstructured":"Weinblatt, M. E. et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N. Engl. J. Med. 312, 818\u2013822 (1985).","journal-title":"N. Engl. J. Med."},{"key":"373_CR102","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/art.1780280702","volume":"28","author":"HJ Williams","year":"1985","unstructured":"Williams, H. J. et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum. 28, 721\u2013730 (1985).","journal-title":"Arthritis Rheum."},{"key":"373_CR103","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/art.1780290702","volume":"29","author":"JM Kremer","year":"1986","unstructured":"Kremer, J. M. & Lee, J. K. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum. 29, 822\u2013831 (1986).","journal-title":"Arthritis Rheum."},{"key":"373_CR104","unstructured":"US Food and Drug Administration. Drug approval package. accessdata.fda.gov https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/204824Orig2s000TOC.cfm (2014)."},{"key":"373_CR105","unstructured":"US Food and Drug Administration. Rasuvo (methotrexate) injection accessdata.fda.gov. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/205776Orig1s000TOC.cfm (2015)."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41584-020-0373-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-020-0373-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-020-0373-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T18:21:29Z","timestamp":1684606889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-020-0373-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,17]]},"references-count":105,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["373"],"URL":"https:\/\/doi.org\/10.1038\/s41584-020-0373-9","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,17]]},"assertion":[{"value":"10 January 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.N.C. declares that he holds equity in Regenosine, a biotech start-up developing therapies for osteoarthritis, and CanFite Biopharma, that he has received grant support from AstraZeneca and Kairos Inc., and that he has a number of patents involving adenosine receptors and hepatic fibrosis, wound healing, bone regeneration and osteoarthritis. T.M.A. declares that he has no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}